A retrospective study to determine real-world outcomes and health care resource utilization of disease-modifying therapy in patients with spinal muscular atrophy type 2 in US
Latest Information Update: 08 Dec 2022
At a glance
- Drugs Nusinersen (Primary) ; Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
Most Recent Events
- 08 Dec 2022 New trial record
- 09 Nov 2022 Results presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research